Retrospective Analysis of Long-Term Adherence to and Persistence with DPP-4 Inhibitors in US Adults with Type 2 Diabetes Mellitus

Advances in Therapy

Volumn 31, Issue 12, 2014, Pages 1287-1305

  Farr, Amanda M ^a   Sheehan, John J ^b   Curkendall, Suellen M ^a   Smith, David M ^a   Johnston, Stephen S ^a   Kalsekar, Iftekhar ^b  

^a IBM WATSON HEALTH   (United States)

^b ASTRAZENECA   (United Kingdom)

Author keywords

Adherence; Dipeptidyl peptidase 4 inhibitors; Persistence; Type 2 diabetes mellitus

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; DIPEPTIDYL PEPTIDASE IV INHIBITOR; SAXAGLIPTIN; SITAGLIPTIN; SULFONYLUREA DERIVATIVE; ADAMANTANE; ANTIDIABETIC AGENT; DIPEPTIDE;

ADULT; ARTICLE; DIABETIC PATIENT; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT COMPLIANCE; RETROSPECTIVE STUDY; UNITED STATES; AGED; ANALOGS AND DERIVATIVES; COHORT ANALYSIS; DIABETES MELLITUS, TYPE 2; LONG TERM CARE; MEDICARE; MEDICATION COMPLIANCE; MIDDLE AGED; PROPORTIONAL HAZARDS MODEL; STATISTICAL MODEL; STATISTICS AND NUMERICAL DATA;

ADAMANTANE; ADULT; AGED; COHORT STUDIES; DIABETES MELLITUS, TYPE 2; DIPEPTIDES; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; LOGISTIC MODELS; LONG-TERM CARE; MALE; MEDICARE; MEDICATION ADHERENCE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; SITAGLIPTIN PHOSPHATE; SULFONYLUREA COMPOUNDS; UNITED STATES;

EID: 84919845727     PISSN: 0741238X     EISSN: 18658652     Source Type: Journal    
DOI: 10.1007/s12325-014-0171-3     Document Type: Article

References (29)

1. Centers for Disease Control and Prevention. National diabetes fact sheet: national estimates and general information on diabetes and prediabetes in the United States, 2011. http://www.cdc.gov/diabetes/pubs/pdf/ndfs_2011.pdf. Accessed Jan 31 2014.
2. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2012;35:1364–79.
3. Garber AJ, Abrahamson MJ, Barzilay JI, et al. American Association of Clinical Endocrinologists’ comprehensive diabetes management algorithm 2013 consensus statement. Endocr Pract. 2013;19:1–48.
4. Centers for Medicare and Medicaid Services. Part C and D Performance Data. http://www.cms.gov/Medicare/Prescription-Drug-Coverage/PrescriptionDrugCovGenIn/PerformanceData.html. Accessed Mar 17 2014.
5. Asche C, LaFleur J, Conner C. A review of diabetes treatment adherence and the association with clinical and economic outcomes. Clin Ther. 2011;33:74–109.
6. Donnelly LA, Morris AD, Evans JM. DARTS/MEMO Collaboration. Adherence to insulin and its association with glycaemic control in patients with type 2 diabetes. QJM. 2007;100:345–50.
7. Ho PM, Rumsfeld JS, Masoudi FA, et al. Effect of medication nonadherence on hospitalization and mortality among patients with diabetes mellitus. Arch Intern Med. 2006;166:1836–41.
8. Rozenfeld Y, Hunt JS, Plauschinat C, Wong KS. Oral antidiabetic medication adherence and glycemic control in managed care. Am J Manag Care. 2008;14:71–5.
9. Breitscheidel L, Stamenitis S, Dippel FW, Schoffski O. Economic impact of compliance to treatment with antidiabetes medication in type 2 diabetes mellitus: a review paper. J Med Econ. 2010;13:8–15.
10. Curkendall SM, Thomas N, Bell KF, Juneau PL, Weiss AJ. Predictors of medication adherence in patients with type 2 diabetes mellitus. Curr Med Res Opin. 2013;29:1275–86.
11. Roebuck MC, Liberman JN, Gemmill-Toyama M, Brennan TA. Medication adherence leads to lower health care use and costs despite increased drug spending. Health Aff (Millwood). 2011;30:91–9.
12. White TJ, Vanderplas A, Chang E, Dezii CM, Abrams GD. The costs of non-adherence to oral antihyperglycemic medication in individuals with diabetes mellitus and concomitant diabetes mellitus and cardiovascular disease in a managed care environment. Dis Manage Health Outcomes. 2004;12:181–8.
13. Jha AK, Aubert RE, Yao J, Teagarden JR, Epstein RS. Greater adherence to diabetes drugs is linked to less hospital use and could save nearly $5 billion annually. Health Aff (Millwood). 2012;31:1836–46.
14. Cramer JA. A systematic review of adherence with medications for diabetes. Diabetes Care. 2004;27:1218–24.
15. Cramer JA, Benedict A, Muszbek N, Keskinaslan A, Khan ZM. The significance of compliance and persistence in the treatment of diabetes, hypertension, and dyslipidaemia: a revew. Int J Clin Pract. 2008;62:76–87.
16. Willliams JL, Walker RJ, Smalls BL, Campbell JA, Egede LE. Effective interventions to improve medication adherence in Type 2 diabetes: a systematic review. Diabetes Manag (Lond). 2014;4:29–48.
17. Malmenas M, Bouchard JR, Langer J. Retrospective real-world adherence in patients with type 2 diabetes initiating once-daily liraglutide 1.8 mg or twice-daily exenatide 10 µg. Clin Ther. 2013;35:795–807.
18. Yang Y, Thumula V, Pace PF, Banahan BF 3rd, Wilkin NE, Lobb WB. Predictors of medication nonadherence among patients with diabetes in Medicare Part D programs: a retrospective cohort study. Clin Ther. 2009;31:2178–2188 (discussion 2150–2171).
19. Gregoire JP, Sirois C, Blanc G, Poirier P, Moisan J. Persistence patterns with oral antidiabetes drug treatment in newly treated patients: a population-based study. Value Health. 2010;13:820–8.
20. Rathmann W, Kostev K, Gruenberger JB, Dworak M, Bader G, Giani G. Treatment persistence, hypoglycaemia and clinical outcomes in type 2 diabetes patients with dipeptidyl peptidase-4 inhibitors and sulphonylureas: a primary care database analysis. Diabetes Obes Metab. 2013;15:55–61.
21. Truven Health Analytics. MarketScan Bibliography. Available from: http://sites.truvenhealth.com/bibliography/2014TruvenHealthMarketScanBibliography.pdf.
22. Peterson AM, Nau DP, Cramer JA, Benner J, Gwadry-Sridhar F, Nichol M. A checklist for medication compliance and persistence studies using retrospective databases. Value Health. 2007;10:3–12.
23. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol. 1992;45:613–9.
24. Gibson TB, Song X, Alemayehu B, et al. Cost sharing, adherence, and health outcomes in patients with diabetes. Am J Manag Care. 2010;16:589–600.
25. Inzucchi SE. Oral antihyperglycemic therapy for type 2 diabetes: scientific review. JAMA. 2002;287:360–72.
26. Malone M. Medications associated with weight gain. Ann Pharmacother. 2005;39:2046–55.
27. Betteridge DJ. Thiazolidinediones and fracture risk in patients with type 2 diabetes. Diabet Med. 2011;28:759–71.
28. Bristol-Myers Squib. Saxagliptin Prescribing Information. http://packageinserts.bms.com/pi/pi_onglyza.pdf. Accessed Mar 17 2014.
29. Merck. Sitagliptin Prescribing Information. http://www.merck.com/product/usa/pi_circulars/j/januvia/januvia_pi.pdf. Accessed Mar 17 2014.